Analgesia News and Research RSS Feed - Analgesia News and Research

Union Hospital expands use of capnography to strengthen patient safety

Union Hospital expands use of capnography to strengthen patient safety

Union Hospital recently strengthened patient safety measures by expanding its use of capnography to monitor patients capnography during patient-controlled analgesia (PCA) to regulate their pain after surgery. [More]
Henrik Kehlet recognized with ASA's 2014 Excellence in Research Award

Henrik Kehlet recognized with ASA's 2014 Excellence in Research Award

The American Society of Anesthesiologists today presented Henrik Kehlet, M.D., Ph.D., with its 2014 Excellence in Research Award in recognition of his outstanding contributions to research which have had an important impact on anesthesiology as a medical specialty. [More]
Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV is defined as any episode of emesis or use of antiemetic rescue medication in the first 24 hours after surgery). [More]
Depression contributes to abnormal pain processes in IBS patients

Depression contributes to abnormal pain processes in IBS patients

High rates of anxiety and depression amongst patients with irritable bowel syndrome (IBS) have led many researchers to believe there could be a causal relationship between psychological factors and IBS symptoms. Now, scientists in Germany have found clear evidence that patients with IBS process pain signals from the gut abnormally, and that disturbed brain responses to pain are particularly pronounced in patients with more depression symptoms. [More]
AcelRx plans for resubmission of Zalviso NDA

AcelRx plans for resubmission of Zalviso NDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update on the plans for the resubmission of the Company's New Drug Application (NDA) for Zalviso (sufentanil sublingual tablet system). [More]
Desaturation 'area under the curve' may help in monitoring patient safety during procedures

Desaturation 'area under the curve' may help in monitoring patient safety during procedures

The "area under the curve of oxygen desaturation" (AUCDesat) may provide a more sophisticated approach to monitoring blood oxygen levels during procedures using sedation, according to a study published in Anesthesia & Analgesia. [More]
Catecholamine polymorphism influences opioid use

Catecholamine polymorphism influences opioid use

The catechol-O-methyltransferase rs4680 single nucleotide polymorphism could affect postoperative opioid consumption, study findings show. [More]
Vitamin D deficiency linked to higher surgical risk

Vitamin D deficiency linked to higher surgical risk

Patients with low blood levels of vitamin D are at increased risk of death and serious complications after noncardiac surgery, suggests a study in Anesthesia & Analgesia. [More]
SCILEX completes patient enrollment to study Ztlido for treatment of postherpetic neuralgia

SCILEX completes patient enrollment to study Ztlido for treatment of postherpetic neuralgia

SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of late-stage pharmaceutical products focused on the treatment of pain, announced today that it has completed patient enrollment for the dermal safety studies and the pivotal pharmacokinetic study related to its investigational product Ztlido (lidocaine patch 1.8%), a next-generation branded lidocaine patch for the treatment of postherpetic neuralgia, also referred to as "after-shingles pain." [More]
New anesthesia procedure demonstrates cause of obstruction in patients with severe sleep apnea

New anesthesia procedure demonstrates cause of obstruction in patients with severe sleep apnea

A simplified anesthesia procedure may enable more widespread use of preoperative testing to demonstrate the cause of airway obstruction in patients with severe sleep apnea, suggests a study in Anesthesia & Analgesia. [More]
FDA issues Complete Response Letter for AcelRx's Zalviso NDA

FDA issues Complete Response Letter for AcelRx's Zalviso NDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's new drug application (NDA) for Zalviso (sufentanil sublingual tablet system). [More]
FDA approves Targiniq ER to treat severe pain

FDA approves Targiniq ER to treat severe pain

Today, the U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. [More]
Severe pain during and post delivery linked to postpartum depression

Severe pain during and post delivery linked to postpartum depression

Controlling pain during childbirth and post delivery may reduce the risk of postpartum depression, writes Katherine Wisner, M.D., a Northwestern Medicine- perinatal psychiatrist, in a July 23 editorial in Anesthesia & Analgesia. [More]
Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

Firstly, paracetamol has been the first-line recommended treatment for osteoarthritis pain for very many years and, secondly, it is readily available over the counter and can be bought in relatively large quantities. [More]
'Pure mass of HES molecules' explains toxicity to renal tubule cells

'Pure mass of HES molecules' explains toxicity to renal tubule cells

The increased risk of kidney injury related to the use of hydroxyethyl starch (HES) in resuscitation fluids reflects the mass of HES molecules, according to a report in Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS). [More]
Kaleo announces U.S. availability of EVZIO for emergency treatment of opioid overdose

Kaleo announces U.S. availability of EVZIO for emergency treatment of opioid overdose

Kaleo, a privately-held pharmaceutical company headquartered in Richmond, Virginia, today announced the United States (U.S.) commercial availability of EVZIO for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. [More]

Grunenthal Group submits Marketing Authorization Application to EMA for ZALVISO

AcelRx Pharmaceuticals, Inc. and Grunenthal Group announced today that Grunenthal has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for ZALVISO for the management of moderate to severe acute pain in adult patients in a medically supervised environment. [More]

Openanesthesia introduces OA Self-Study App for iOS and Android devices

The OA Self-Study App for iOS and Android devices is designed to help resident anesthesiologists, physicians, and those in the related health professions to improve their knowledge of basic and advanced concepts of the field. [More]
Trevena's Phase 1b data for TRV130 published in the journal Pain

Trevena's Phase 1b data for TRV130 published in the journal Pain

Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain. [More]
BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today it has in-licensed BL-1110, a novel compound for the treatment of neuropathic pain. [More]